Lexeo Therapeutics, Inc. · Brief

Next report

4 days

Nov 4 · before openest.Q3 FY26

Expected move

No implied move.

8 reportsHistory

0 of 6≥ implied

Nov 13 '24—▼−0.65%—

Mar 24 '25±51.0%▲+50.92%×1.00

May 12 '25±25.8%▼−2.23%×0.09

Aug 14 '25±12.6%▲+1.48%×0.12

Q3 FY25±15.7%▼−1.80%×0.11

Q1 FY26—▲+8.92%—

May 11 '26±60.6%▲+4.97%×0.08

Q2 FY26±70.2%▲+1.88%×0.03

quarterimplied−75%0+75%realized×

Q2 FY26±70.2%▲+1.88%×0.03

May '26±60.6%▲+4.97%×0.08

Q1 FY26—▲+8.92%—

Q3 FY25±15.7%▼−1.80%×0.11

Aug '25±12.6%▲+1.48%×0.12

May '25±25.8%▼−2.23%×0.09

2 older reports

Mar '25±51.0%▲+50.92%×1.00

Nov '24—▼−0.65%—

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Nov 4 report · est.

Bull2 of 4

143managers reporting a position in the latest quarterly filings13F · Jun 30 '26

+13.98%change in shares held by the ten largest reporting managers over the latest quarter13F · Jun 30 '26

Bear2 of 3

6 of 6recent reports where the move came in under the options-implied rangeEarnings history

0.11%of State Street SPDR S&P Biotech ETF's assets, the largest tracked-fund weightN-PORT · Jun 30 '26

AI captions · Sep 28 '26once per report · top 2 per case

LXEO report session

No linked exposure.

Oct 28impliedImplied move: ±30.6% into Nov 4 earnings (Oct 28 close).Source

privateThesis 0 · Decisions 0 · Observations 0

No thesis.